De-ping Zhao , Ao Xue , Ke Yuan , Kun Zuo , Yang Li , Zhen-hua Bian , Hong-dan Xu , Si-min Cheng , Meng Yang , Hong-mei Zhao , Xin Ma , Xia Lei , Ning Zhang
{"title":"Anemarrhena asphodeloides Bunge and Phellodendri Chinensis Cortex inhibits the PTGS2/EP2/cAMP/Epac1 signaling pathway to reduce microglial M1 polarization, thereby blocking chronic stress-induced depression-like behavior","authors":"De-ping Zhao , Ao Xue , Ke Yuan , Kun Zuo , Yang Li , Zhen-hua Bian , Hong-dan Xu , Si-min Cheng , Meng Yang , Hong-mei Zhao , Xin Ma , Xia Lei , Ning Zhang","doi":"10.1016/j.jep.2025.119792","DOIUrl":null,"url":null,"abstract":"<div><h3>Ethnopharmacological relevance</h3><div><em>Anemarrhena asphodeloides</em> Bunge and <em>Phellodendri Chinensis</em> Cortex (AP) is a synergistic drug combination used to treat depression. However, the molecular mechanism underlying the therapeuticeffects of AP requires further elucidation.</div></div><div><h3>Aim of the study</h3><div>To investigate the potential of AP in the treatment of depression and its mechanism of action.</div></div><div><h3>Methods and methods</h3><div>The depression model was established by chronic unpredictable mild stress (CUMS) and treated with different doses of AP. UPLC-Q-TOF-MS/MS and network pharmacology methods were used to analyze the composition and potential targets of AP. Molecular docking, affinity ultrafiltration (AUF) and cellular thermal shift assays (CETSA) techniques were used to analyze the interaction between AP components and key targets. The therapeutic effects of AP active ingredients were explored in LPS-induced cell models.</div></div><div><h3>Results</h3><div>AP ameliorated CUMS-induced despair behaviors, regulate M1/M2 phenotypic balance of microglia and reduced neuroinflammation. Then, A total of 10 brain components were identified in the mPFC of CUMS rats. Based on these chemical compositions, PTGS2 was found to be at the core of the regulatory network through network analysis. All components of AP had good interaction with PTGS2, among which Neomangiferin and PTGS2 had the strongest binding capacity. AP can decrease PTGS2 activity, decrease PGE2 production and EP2 expression downstream, and reduce inflammatory response. In LPS-induced BV2 cells, Neomangiferin regulated the imbalance of M1/M2 microglia, reduced the release of pro-inflammatory factors, and decreased the expression of PTGS2, PEG2, EP2, cAMP, and Epac1.</div></div><div><h3>Conclusion</h3><div>AP improves the potential therapeutic benefits of depression by targeting the PTGS2 signaling pathway, thereby promoting the wider use of AP in depression.</div></div>","PeriodicalId":15761,"journal":{"name":"Journal of ethnopharmacology","volume":"347 ","pages":"Article 119792"},"PeriodicalIF":4.8000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of ethnopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378874125004763","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Ethnopharmacological relevance
Anemarrhena asphodeloides Bunge and Phellodendri Chinensis Cortex (AP) is a synergistic drug combination used to treat depression. However, the molecular mechanism underlying the therapeuticeffects of AP requires further elucidation.
Aim of the study
To investigate the potential of AP in the treatment of depression and its mechanism of action.
Methods and methods
The depression model was established by chronic unpredictable mild stress (CUMS) and treated with different doses of AP. UPLC-Q-TOF-MS/MS and network pharmacology methods were used to analyze the composition and potential targets of AP. Molecular docking, affinity ultrafiltration (AUF) and cellular thermal shift assays (CETSA) techniques were used to analyze the interaction between AP components and key targets. The therapeutic effects of AP active ingredients were explored in LPS-induced cell models.
Results
AP ameliorated CUMS-induced despair behaviors, regulate M1/M2 phenotypic balance of microglia and reduced neuroinflammation. Then, A total of 10 brain components were identified in the mPFC of CUMS rats. Based on these chemical compositions, PTGS2 was found to be at the core of the regulatory network through network analysis. All components of AP had good interaction with PTGS2, among which Neomangiferin and PTGS2 had the strongest binding capacity. AP can decrease PTGS2 activity, decrease PGE2 production and EP2 expression downstream, and reduce inflammatory response. In LPS-induced BV2 cells, Neomangiferin regulated the imbalance of M1/M2 microglia, reduced the release of pro-inflammatory factors, and decreased the expression of PTGS2, PEG2, EP2, cAMP, and Epac1.
Conclusion
AP improves the potential therapeutic benefits of depression by targeting the PTGS2 signaling pathway, thereby promoting the wider use of AP in depression.
期刊介绍:
The Journal of Ethnopharmacology is dedicated to the exchange of information and understandings about people''s use of plants, fungi, animals, microorganisms and minerals and their biological and pharmacological effects based on the principles established through international conventions. Early people confronted with illness and disease, discovered a wealth of useful therapeutic agents in the plant and animal kingdoms. The empirical knowledge of these medicinal substances and their toxic potential was passed on by oral tradition and sometimes recorded in herbals and other texts on materia medica. Many valuable drugs of today (e.g., atropine, ephedrine, tubocurarine, digoxin, reserpine) came into use through the study of indigenous remedies. Chemists continue to use plant-derived drugs (e.g., morphine, taxol, physostigmine, quinidine, emetine) as prototypes in their attempts to develop more effective and less toxic medicinals.